Literature DB >> 25085666

Merkel cell carcinoma: current status of targeted and future potential for immunotherapies.

Bishr Aldabagh1, Jayne Joo, Siegrid S Yu.   

Abstract

Merkel cell carcinoma is an aggressive neuroendocrine tumor with a high incidence of local recurrence, regional nodal and distant metastasis, and a high mortality rate. It has been linked to a polyomavirus in addition to immune suppression. Traditionally, treatment options have been limited to surgery and radiation therapy. Better understanding of the molecular pathways of infection and carcinogenesis has provided potential molecular targets and potential immunotherapies which are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25085666     DOI: 10.12788/j.sder.0084

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  4 in total

1.  Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications.

Authors:  Philip R Cohen; Razelle Kurzrock
Journal:  Dermatol Ther (Heidelb)       Date:  2015-04-15

2.  Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.

Authors:  Philip R Cohen; Brett N Tomson; Sheryl K Elkin; Erica Marchlik; Jennifer L Carter; Razelle Kurzrock
Journal:  Oncotarget       Date:  2016-04-26

3.  Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.

Authors:  Cathrin Ritter; Kaiji Fan; Annette Paschen; Sine Reker Hardrup; Soldano Ferrone; Paul Nghiem; Selma Ugurel; David Schrama; Jürgen C Becker
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

Review 4.  Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Authors:  Paul Nghiem; Howard L Kaufman; Murtuza Bharmal; Lisa Mahnke; Hemant Phatak; Jürgen C Becker
Journal:  Future Oncol       Date:  2017-03-28       Impact factor: 3.404

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.